Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Essential Amino Acids High Clear all
Completed Phase 3 Interventional Results available

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

NCT00624065
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol controlled release/lisinopril, lisinopril + placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Intake and Circulating Levels of Branched Chain Amino Acids

NCT02110602
View directory record Official record
Conditions
Dietary Intake of Branched Chain Amino Acids
Interventions
Diet high in amino acid levels, Diet low in amino acid levels
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 40 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

NCT00446511
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

NCT00513617
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Arginine, Placebo
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
5 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
17
States / cities
Oakland, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Essential Amino Acids and Protein Kinetics During Caloric Deprivation

NCT03372928
View directory record Official record
Conditions
Muscle Protein Synthesis, Whole-body Protein Balance
Interventions
Standard EAA, High EAA
Dietary Supplement
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

NCT00696436
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Valsartan, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

NCT02151461
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Metformin, Mid Metformin, High Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

NCT00386607
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 4 Interventional Results available

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

NCT02816736
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ696, valsartan, LCZ696 placebo, valsartan placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Beverly Hills, California • Sacramento, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

NCT01105130
View directory record Official record
Conditions
Male Erectile Disorder, Prostate Cancer, Radiation Toxicity
Interventions
Placebo, Oral L-Arginine
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Long-term Effects of Oceanix™ on Resistance Training Adaptations

NCT04136821
View directory record Official record
Conditions
Oxidative Stress, Muscle Strength, Resistance Training, Body Composition, Muscle Damage
Interventions
Oceanix, Resistance Training
Dietary Supplement · Other
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 1 Interventional

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004904
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 17, 2026, 2:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
D. Walter Wray
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preserving Muscle Mass and Function in Bedridden Older Adults

NCT01846130
View directory record Official record
Conditions
Bed Rest
Interventions
Leucine, Exercise, Whey protein
Dietary Supplement · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

NCT02435277
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Mid Metformin, High Metformin, Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 17, 2026, 2:39 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature

NCT05067998
View directory record Official record
Conditions
Anxiety Disorders and Symptoms, Fibromyalgia, Arthritis, Chronic Pain, Hypertension,Essential
Interventions
IV Vitamin Infused Therapy Treatment, Herbal medicine
Dietary Supplement · Drug
Lead sponsor
Faith A. Richardson
Other
Eligibility
21 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dover, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

NCT00097786
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 99 Years
Enrollment
9,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Multiple Locations, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 17, 2026, 2:39 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

NCT03686657
View directory record Official record
Conditions
Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions
Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
Drug
Lead sponsor
ARKAY Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Active, not recruiting Not applicable Interventional

Assessing The Effects of Exercise, Protein, and Electric Stimulation On Intensive Care Unit Patients Outcomes

NCT02509520
View directory record Official record
Conditions
Muscle Weakness, Critical Illness, Sarcopenia
Interventions
MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Terminated Not applicable Interventional Results available

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

NCT01252238
View directory record Official record
Conditions
Insulin Sensitivity, Aortic Compliance, Diastolic Function
Interventions
Aliskiren, Valsartan and Aliskiren, Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 17, 2026, 2:39 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

NCT01432106
View directory record Official record
Conditions
Hypertension, Metabolic Syndrome
Interventions
Aliskerin/Valsartan and Rampiril
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Results available

Phase Ib of L-NMMA and Pembrolizumab

NCT03236935
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma Bladder, DNA Repair-Deficiency Disorders
Interventions
L-NMMA, Pembrolizumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Short Term Effects of Oceanix Supplementation on Recovery

NCT04315077
View directory record Official record
Conditions
Oxidative Stress, Muscle Strength, Resistance Training, Muscle Damage, Immune Suppression
Interventions
Oceanix®, Resistance Training
Dietary Supplement · Other
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 17, 2026, 2:39 AM EDT